27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Intraindividual cognitive variability (IIV), a measure of within-person variability across cognitive measures at a single time point, is associated with mild cognitive impairment (MCI) and Alzheimer's disease (AD). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Racial and ethnic differences in Alzheimer's disease (AD) and related dementias are well documented. 4 key findings →
Participants: 18,550 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In China, the crude mortality from AD and other forms of dementia increased from 2009 to 2015, but the age-standardized mortality decreased. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Multiple challenges were encountered in creating a sampling framework and contacting, recruiting and retaining care homes in the PACE study. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
A plethora of complex misfolded protein combinations have been found in Alzheimer disease (AD) brains besides the classical pathological hallmarks. 2 key findings →
Participants: 39 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Neurofilament light chain (NFL) has been recently introduced as a biomarker of early dementia. 18-Fluorodeoxyglucose positron emission tomography (18F-FDG-PET) is a proxy for regional hypometabolism in Alzheimer disease (AD). 1 key finding →
Participants: 149 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
This study will provide evidences to evaluate the efficacy and safety of SMYZD in combination with GBEs in treatment of VaD, as well as the adjuvant role of SMYZD in combination. 5 key findings →
Participants: 196 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's disease (AD) is the most common cause of dementia in the elderly and the sixth leading cause of death in the United States. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Machine learning has become ubiquitous and a key technology on mining electronic health records (EHRs) for facilitating clinical research and practice. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Machine learning models are promising alternatives for estimating the genetic risk of LOAD. 3 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The clinical symptoms of dementia include difficulty with speech, poor short-term memory, and changes in behavior. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Down syndrome (DS) is the main genetic cause of intellectual disability worldwide. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
No disease-modifying therapy is currently available for Alzheimer's disease, but therapies are in development, and one may become available in the near future. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Variants in the gene encoding the triggering receptor expressed on myeloid cells 2 (TREM2) are known to increase the risk of developing Alzheimer disease and Parkinson's disease (PD). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Microglia have important remodeling functions in neurodevelopment, aging, and disease, with evidence for molecular diversity. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Adipose tissue remodeling plays a significant role in obesity-induced insulin resistance. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Human and animal studies suggest that inflammation occurring outside the central nervous system (systemic inflammation) may play a key role in promoting neurodegeneration, Alzheimer's disease pathology, and cognitive decline in older adults. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The national prevalence and incidence of registered dementia diagnoses was 3.0% and 0.5%, respectively. 4 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
As our population ages, therapies increase, and the number of individuals living with advanced PD and related disorders grows, so too does the imperative to recognize and address the palliative care needs of such patients and families. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The sleep-wake cycle regulates interstitial fluid (ISF) and cerebrospinal fluid (CSF) levels of β-amyloid (Aβ) that accumulates in Alzheimer's disease (AD). 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Insulin resistance is a major risk factor for Alzheimer's disease (AD). 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Noncoding genetic variation is a major driver of phenotypic diversity, but functional interpretation is challenging. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Cerebral blood flow is reduced early in the onset of Alzheimer's disease (AD). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
CSF-NEP was significantly inversely associated with CSF-Aβ42 and positively with the extent of neuronal injury as measured by CSF-tau and FDG-PET. 3 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
The We and others have previously shown that polygenic risk score analysis (PRS) has considerable predictive utility for identifying those at high risk of developing Alzheimer's disease (AD) with an area under the curve (AUC) of >0.8. 3 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →